Lung India最新文献

{"title":"Anti-inflammatory reliever therapy for asthma in India - Can we be SMARTer.","authors":"Nipun Malhotra, Vidushi Rathi, Pranav Ish","doi":"10.4103/lungindia.lungindia_46_25","DOIUrl":"10.4103/lungindia.lungindia_46_25","url":null,"abstract":"","PeriodicalId":47462,"journal":{"name":"Lung India","volume":"42 4","pages":"477-479"},"PeriodicalIF":1.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12342194/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144601930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the possibility of a predictable precision therapy of COPD with inclusion of glycopyrronium responsiveness: A real-world experience.","authors":"Parthasarathi Bhattacharyya, Shuvam Ghosh, Srijita Sen, Debkanya Dey, Sayoni Sengupta, Saayon Bej, Avishek Kar, Dipanjan Saha","doi":"10.4103/lungindia.lungindia_54_25","DOIUrl":"10.4103/lungindia.lungindia_54_25","url":null,"abstract":"<p><strong>Background: </strong>The advent of glycopyrronium responsiveness has opened the prospect of selective responsiveness-based prescription of bronchodilators-β2-agonists or anti-muscarinic agents (AMA) for COPD. Such a concept needs ratification through clinical trials.</p><p><strong>Methods: </strong>Stable COPD patients [post-bronchodilator FEV1/FVC <0.7] underwent serial glycopyrronium responsiveness [≥100 ml FEV1-improvement] after salbutamol before universal prescription of LABA-LAMA ± ICS as per guideline recommendation. At real-world follow-up, we noted the adverse and serious adverse events (exacerbations and hospitalizations) and, whenever possible, repeated spirometry in the similar fashion. Based on the initial glycopyrronium responsiveness, we divided the patients into glycopyrronium-sensitive and non-sensitive groups and compared the impact of treatment between them using spirometric variables (FEV1, FVC, FEV1/FVC and FEF25-75). We compared the 'trough'-FEV1 and 'total'-FEV1 (difference from the initial pre-bronchodilator to final post-dual-bronchodilator values) along with the frequency of exacerbation and hospitalization in each group.</p><p><strong>Results: </strong>The glycopyrronium-responsive and non-responsive groups (n = 30 for each) were similar demographically and on initial spirometry (pre-bronchodilator and post-salbutamol values). They received treatment for 162.4 ± 134.8 and 212 ± 118.1 days, respectively. The glycopyrronium-sensitive patients displayed significant improvement in both trough-FEV1 [0.17 ± 0.29 vs. 0.02 ± 0.2; (P = 0.0308)], total-FEV1 [0.32 ± 0.29 vs. 0.17 ± 0.21; (P = 0.0273) litres], in addition to trough FEF25-75 (P = 0.0204), total FEV1/FVC (0.0174) and total FEF25-75 (P = 0.0322). The exacerbations (P = 0.0056) were significantly lower in glycopyrronium-responsive patients.</p><p><strong>Conclusion: </strong>The glycopyrronium-responsive COPD patients show a significantly better overall improvement including the significant change in trough and total FEV1 with significantly reduced exacerbations in the real-world observation. The revelation demands more research.</p>","PeriodicalId":47462,"journal":{"name":"Lung India","volume":"42 4","pages":"322-329"},"PeriodicalIF":1.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12342199/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144498297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re-use of EBUS needles: The elephant in the room.","authors":"Pratibha Jha, Rajiv Goyal, V R Pattabhiraman","doi":"10.4103/lungindia.lungindia_298_25","DOIUrl":"10.4103/lungindia.lungindia_298_25","url":null,"abstract":"","PeriodicalId":47462,"journal":{"name":"Lung India","volume":"42 4","pages":"279-280"},"PeriodicalIF":1.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12342206/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144498299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CAT score as a prognostic tool in low resource setting: Exploring the correlation between CAT score, exacerbation history with BODE Index in stable COPD.","authors":"Jocelyn Anna Joseph, Vishwanath Vasant Pujari","doi":"10.4103/lungindia.lungindia_633_24","DOIUrl":"10.4103/lungindia.lungindia_633_24","url":null,"abstract":"<p><strong>Background: </strong>Chronic obstructive pulmonary disease (COPD) is a significant global health concern, projected to be the fourth leading cause of death by 2030. This study explores the correlation between the COPD assessment test (CAT) score, history of exacerbations, and the BODE Index in stable COPD patients. While the BODE Index is a validated multidimensional grading system, its application in outpatient settings, especially in resource-constrained setting, can be challenging due to the need for spirometry.</p><p><strong>Methods: </strong>We conducted a cross sectional, observational study. It was conducted over 18 months in Mumbai and recruited 50 stable COPD patients. The CAT score and history of exacerbations in the previous year were evaluated alongside the BODE Index and other demographic data.</p><p><strong>Statistical: </strong>The correlation between quantitative variables was performed using Pearson and Spearman's correlation coefficient, with P < 0.05 considered statistically significant.</p><p><strong>Results: </strong>In the study population, the mean rate of exacerbation observed was 1.52 (SD = 2.279)/person/year, and the mean CAT score was 9.88 ± 7.34 (range: 0-27). The median BODE Index was 3 with most of the patients 44% (n = 22) having a BODE score falling in the first quartile. Positive correlations r (Pearson's) =0.468 (P = 0.000614) and σ (Spearman's) =0.2797 (P = 0.0490) were observed between CAT score with BODE Index and exacerbation history and BODE Index, respectively, indicating a moderate positive correlation between CAT score and BODE Index and statistically significant, albeit weak, correlation with exacerbation history.</p><p><strong>Conclusions: </strong>Our findings suggest that simple tools like CAT and exacerbation history can be used as surrogates for the BODE Index.</p>","PeriodicalId":47462,"journal":{"name":"Lung India","volume":"42 4","pages":"343-346"},"PeriodicalIF":1.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12342215/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144498379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A comparative cloud-based view of adherence data over 1 year of CPAP versus APAP uses in OSA patients: Adherence depends on PAP device.","authors":"Arup K Haldar, Raja Dhar, Somnath Maity, Shyam Krishnan, Amrita Bhattacharya, Milind Sovani","doi":"10.4103/lungindia.lungindia_572_24","DOIUrl":"10.4103/lungindia.lungindia_572_24","url":null,"abstract":"<p><strong>Introduction: </strong>Compliance or adherence with positive airway pressure (PAP) therapy is a major issue in obstructive sleep apnea (OSA). The telemonitoring gives an opportunity to track a group of patients on cloud-based devices. In this study, we followed up patients with this cloud-based method for more than a year and followed up two different cohorts who are on continuous PAP (CPAP) and auto adjusting PAP (APAP) devices. The main objective was to judge whether one device scores over the other.</p><p><strong>Methods: </strong>This was a retrospective study. We included 60 patients in the CPAP group and 80 patients in the APAP group in the study who are using the device for 1 year or more; they all were on cloud-based devices, and for them, we had data of completed 1 year at least. The data were reviewed periodically for compliance, AHI (Apnea-Hypopnea Index), and leak and compared.</p><p><strong>Results: </strong>Both the groups were matched in terms of age, BMI, and AHI. Adherence at 365 days was significantly more (P < 0.001) for CPAP than APAP. Overall adherence was not lesser than 60% for CPAP in any patient. The mean AHI was 1.48 in CPAP group and 2.30 in APAP group. When we measured the leak in CPAP versus APAP group, it was 0.53 liter/minute more in CPAP group than in APAP group, but it was statistically non-significant (P = 0.8553). The mean pressure level between APAP and CPAP was 11.11 cmH2O in CPAP group and 11.62 cm H2O in APAP group, and it was again statistically non-significant (P = 0.1960). CPAP group used the machine 5.77 hours average, while APAP group used it for 4.51 hours average.</p><p><strong>Conclusion: </strong>CPAP adherence at 1 year was better over APAP in this study, which has a large cost implication.</p>","PeriodicalId":47462,"journal":{"name":"Lung India","volume":"42 3","pages":"186-190"},"PeriodicalIF":1.3,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12097661/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143990662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Berry syndrome: A rare myriad of cardiopulmonary vascular anomalies.","authors":"Anmol Bhatia, Parveen Kumar, Akshay Kumar Saxena, Kushaljit Singh Sodhi","doi":"10.4103/lungindia.lungindia_82_25","DOIUrl":"10.4103/lungindia.lungindia_82_25","url":null,"abstract":"","PeriodicalId":47462,"journal":{"name":"Lung India","volume":"42 3","pages":"269-270"},"PeriodicalIF":1.3,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12097672/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144035082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improving patient outcomes: Mepolizumab's impact in IL-5-mediated diseases.","authors":"Dipti Gothi, Raghupathi Narasimhan, Randeep Guleria, Manu Chopra, Aanchal Gvalani, Rashmi Hegde","doi":"10.4103/lungindia.lungindia_442_24","DOIUrl":"10.4103/lungindia.lungindia_442_24","url":null,"abstract":"<p><strong>Abstract: </strong>The Interleukin-5 (IL-5)-mediated pathogenic role of eosinophils in airway disorders including severe eosinophilic asthma (SEA), chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic granulomatosis with polyangiitis (EGPA), and rare hyper-eosinophilic syndrome (HES) is well established. Mepolizumab, an IL-5-targeting humanised antibody, is approved as an add-on maintenance therapy for SEA, EGPA, CRSwNP, and HES. Here, we review the safety and efficacy findings of mepolizumab in clinical trials and real-world evidence studies in patients with SEA, CRSwNP, EGPA, and HES. We specifically explore the data on mepolizumab that support early initiation of IL-5-targeted therapy to maximise its corticosteroid-sparing effect. This review consolidates the clinical data on mepolizumab, highlights other promising IL-5-targeting agents, and supports the IL-5 pathway as the key therapeutic target across eosinophilic indications.</p>","PeriodicalId":47462,"journal":{"name":"Lung India","volume":"42 3","pages":"231-244"},"PeriodicalIF":1.3,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12097673/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144041718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endobronchial ultrasound transbronchial needle aspiration in the diagnosis of visceral leishmaniasis in a patient with human immunodeficiency virus infection.","authors":"Mohammad A Amjad, Y H Zhang, Rosa M Estrada-Y-Martin, Sujith V Cherian","doi":"10.4103/lungindia.lungindia_64_25","DOIUrl":"10.4103/lungindia.lungindia_64_25","url":null,"abstract":"","PeriodicalId":47462,"journal":{"name":"Lung India","volume":"42 3","pages":"266-267"},"PeriodicalIF":1.3,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12097657/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143989564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A single-centre, randomised trial to compare diagnostic yield and safety between endobronchial cryobiopsy and endobronchial forceps biopsy procedure in patients with endobronchial lesions.","authors":"Swapnendu Misra, Ankan Bandyopadhyay, Anupam Patra, Ritabrata Mitra, Amitava Sengupta, Somenath Kundu","doi":"10.4103/lungindia.lungindia_452_24","DOIUrl":"10.4103/lungindia.lungindia_452_24","url":null,"abstract":"<p><strong>Background: </strong>Flexible bronchoscopy is the diagnostic tool of choice to diagnose endobronchial lesions. Pathological samples can be harvested using various techniques, for example, forceps biopsy, brushing, washing, and recently cryobiopsy. The major drawbacks of forceps biopsy technique are (a) obtaining of smaller tissues and (b) presence of crush artefacts. This results in a significant failure rate. Cryobiopsy is the procedure where application of extreme cold to the pathological tissues is used for obtaining samples. As a cryoprobe allows procurement of larger biopsy samples which is devoid of any crush artefacts, these result in better histopathology, immunohistochemistry, and identification of specific genetic mutations.</p><p><strong>Methods: </strong>The current trial tried to assess (i) the diagnostic yield of endobronchial cryobiopsies in comparison with endobronchial forceps biopsies and (ii) assess the duration of procedures and requirement of interventions to control bleeding, among 49 patients who had undergone forceps biopsy and 48 patients who had undergone cryobiopsy. The types of endobronchial lesions observed during bronchoscopic procedures were divided into (a) exophytic type and (b) infiltrative type. Biopsy interpretations were done by an expert pathologist.</p><p><strong>Results: </strong>Cryobiopsy compared to forceps biopsy had a statistically significant higher diagnostic yield for diagnosis of overall endobronchial lesions (P < 0.0001) for both exophytic (P = 0.015) and infiltrative (P < 0.0001) growth. Cryobiopsy obtained larger tissue (P < 0.001). No statistically significant difference was found in the incidence of haemorrhage (P = 0.378) and duration (P = 0.173) between two procedures.</p><p><strong>Conclusions: </strong>Cryobiopsies were more successful than forceps biopsies particularly for diagnosis of infiltrative growth. The complication rate was similar between the two procedures.</p>","PeriodicalId":47462,"journal":{"name":"Lung India","volume":"42 3","pages":"204-210"},"PeriodicalIF":1.3,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12097659/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144051106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bridging knowledge gaps: A case report of pulmonary Veno-occlusive disease in systemic sclerosis.","authors":"Shivam Garg, Deepansh Gupta, Girish Sindwani","doi":"10.4103/lungindia.lungindia_481_24","DOIUrl":"10.4103/lungindia.lungindia_481_24","url":null,"abstract":"<p><strong>Abstract: </strong>Pulmonary Veno-Occlusive Disease (PVOD) is a rare cause of pulmonary hypertension (PH) in patients with systemic sclerosis (SSc), posing significant diagnostic and therapeutic challenges. Here, we present a case of a patient with systemic sclerosis who presented with symptoms of progressive dyspnea for 1 year. Her chest radiogram was normal, and echocardiography was suggestive of severe PH. She was started on a combination of Ambrisentan and Tadalafil. However, she developed pulmonary edema after the initiation of pulmonary vasodilators. Diagnostic workup, including imaging studies, with clinical and radiological worsening with pulmonary vasodilators, confirmed PVOD in the setting of SSc. The patient gradually improved with diuretic therapy. This case emphasizes the importance of early clinical suspicion and multidisciplinary discussion in managing rare pulmonary complications associated with systemic sclerosis. Additionally, it highlights the urgent need for further research to delineate the underlying pathophysiological mechanisms and optimize therapeutic strategies for this challenging clinical entity.</p>","PeriodicalId":47462,"journal":{"name":"Lung India","volume":"42 3","pages":"248-251"},"PeriodicalIF":1.3,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12097679/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144041041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}